On May 20, 2019, AzurRx BioPharma, Inc. (the “Company”) issued a press release announcing positive secondary endpoint data in its Phase II MS1819-SD Chronic Pancreatits Study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01.Financial Statements and Exhibits.

See Exhibit Index.

AzurRx BioPharma, Inc. Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint    Exhibit 99.1   AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference     ● Statistical significance achieved on multiple secondary endpoints ● New data underscore the potential of MS1819 to provide meaningful clinical benefits to patients suffering from exocrine pancreatic insufficiency (EPI)   NEW YORK,…
To view the full exhibit click here

About AZURRX BIOPHARMA, INC. (NASDAQ:AZRX)

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).